An analysis of six clinical trials found that AOD 9604 had a safety profile comparable to placebo and did not act through the IGF-1 pathway
There is still only a limited number of studies that have attempted to uncover the mechanisms governing necroptosis in erythrocytes, but there is evidence that necroptotic signaling in erythrocytes requires pore formation, necrosome assembly, NADPH oxidase- and Fenton chemistry-derived ROS, glucose-derived advanced glycation end products, ceramide, and Syk-mediated Band 3 protein phosphorylation [17, 198,199,200,201]

Benefits AOD-9604 is believed to help with: Mechanistically designed to support fat breakdown and reduce new fat formation while having minimal direct impact on blood sugar and IGF1. May offer modest additional help with fat metabolism when combined with calorie control and exercise, particularly in higheradiposity individuals. Typically administered as a daily subcutaneous injection in low doses, integrated into a broader metabolic and lifestyle protocol. Longterm clinical safety data show generally good tolerability in studied populations, but regulators have highlighted unresolved immunogenicity and impurity concerns, so usage must remain cautious and fully consented. Positioned as an optional, supportive layernot a standalone weight-loss solutionwith emphasis on lab monitoring, habit coaching, and realistic expectations.
Mentioned in This Article: Vitamin B12 Vitamin B12 is essential for red blood cell formation and DNA production
10.1002/ctm2.70253 111 XiangH.LyuQ.ChenS.OuyangJ.XiaoD.LiuQ.et al (2024)
So, it's approved even for fasting days